TW201628635A - An herbal composition for improving diabetic retinopathy and a use of the herbal composition thereof - Google Patents

An herbal composition for improving diabetic retinopathy and a use of the herbal composition thereof Download PDF

Info

Publication number
TW201628635A
TW201628635A TW104104573A TW104104573A TW201628635A TW 201628635 A TW201628635 A TW 201628635A TW 104104573 A TW104104573 A TW 104104573A TW 104104573 A TW104104573 A TW 104104573A TW 201628635 A TW201628635 A TW 201628635A
Authority
TW
Taiwan
Prior art keywords
extract
diabetic retinopathy
dendrobium
herbal composition
rats
Prior art date
Application number
TW104104573A
Other languages
Chinese (zh)
Inventor
劉崇喜
劉怡旻
洪坤毅
Original Assignee
漢聖製藥科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 漢聖製藥科技股份有限公司 filed Critical 漢聖製藥科技股份有限公司
Priority to TW104104573A priority Critical patent/TW201628635A/en
Publication of TW201628635A publication Critical patent/TW201628635A/en

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

An herbal composition for improving diabetic retinopathy is disclosed. The herbal composition includes 40 wt% of an ethanol extract of Astragalus membranaceus, 8 wt% of an ethanol extract of Angelica sinensis and 52 wt% of a water extract of Dendrobium officinale. A use of the herbal medication is also disclosed.

Description

用以改善糖尿病視網膜病變之中草藥組合物及其用途 Herbal composition for improving diabetic retinopathy and use thereof

本發明係關於一種中草藥組合物,特別係一種用以改善糖尿病視網膜病變之中草藥組合物,本發明另關於該中草藥組合物用以製備改善糖尿病視網膜病變藥物之用途。 The present invention relates to a Chinese herbal medicine composition, in particular to a herbal composition for improving diabetic retinopathy, and to the use of the Chinese herbal medicine composition for preparing a medicament for improving diabetic retinopathy.

糖尿病視網膜病變(diabetic retinopathy)為糖尿病(diabetes)的一種併發症,其係由於高血糖所誘導之血管壁機能不全,因而影響血管一視網膜屏障(blood-retinal barrier)之功能及提升患部血管之通透性等視網膜微循環(capillary circulation)的改變所造成之症狀,此為糖尿病患者致盲的主要原因。 Diabetic retinopathy (diabetic retinopathy) is a complication of diabetes, which is caused by hyperglycemia-induced vascular wall insufficiency, thus affecting the function of the blood-retinal barrier and enhancing the blood vessels of the affected part. Symptoms caused by changes in retinal microcirculation, such as permeability, are the leading cause of blindness in diabetic patients.

習用改善糖尿病視網膜病變之方法包含雷射手術、玻璃體切除術(vitrectomy)及眼部注射皮質類固醇(corticosteroid)等方法,惟三者均屬於侵入性醫療行為,且仍無法達到根治之效果,患者仍需隨時監控自己的血糖,並使自己的血糖維持在正常範圍(euglycemia),而皮質類固醇之投藥更可能造成副作用之發生。據此,習用治療糖尿病視網膜病變之方法仍有改善之必要。 The methods used to improve diabetic retinopathy include laser surgery, vitrectomy, and intraocular injection of corticosteroids. All three are invasive medical behaviors, and still cannot achieve the effect of radical cure. You need to monitor your blood sugar at any time and keep your blood sugar in the normal range (euglycemia), and the administration of corticosteroids is more likely to cause side effects. Accordingly, there is still a need for improved methods for treating diabetic retinopathy.

石斛(Dendrobium officinale)可以應用於降低血糖,進而控制糖尿病相關疾病,亦可以作為治療視網膜疾病之活性成分,惟其針對改善糖尿病視網膜病變之功效仍顯不彰。 Dendrobium officinale can be used to lower blood sugar, thereby controlling diabetes-related diseases. It can also be used as an active ingredient in the treatment of retinal diseases, but its efficacy in improving diabetic retinopathy remains unclear.

本發明係提供一種中草藥組合物,係作為改善糖尿病視網膜病變之活性成份者。 The present invention provides a Chinese herbal medicine composition as an active ingredient for improving diabetic retinopathy.

本發明再提供一種中草藥組合物之用途,係作為改善糖尿病視網膜病變之活性成份,以改善習用治療糖尿病視網膜病變之方法所造成之副作用者。 The invention further provides a use of a Chinese herbal medicine composition as an active ingredient for improving diabetic retinopathy to improve the side effects caused by the conventional method for treating diabetic retinopathy.

一種用以改善糖尿病視網膜病變之中草藥組合物,係包含:以重量百分比計為40%之一黃耆酒萃物、8%之一當歸酒萃物及52%之一石斛水萃物。 A herbal composition for improving diabetic retinopathy comprises: 40% by weight of a sassafras extract, 8% of an angelica extract and 52% of an aqueous extract of Dendrobium.

本發明之用以改善糖尿病視網膜病變之中草藥組合物,其中,該黃耆酒萃物係萃取自一黃耆根部樣品,且係為由體積百分濃度為95%之一乙醇水溶液所萃取獲得。 The herbal composition for improving diabetic retinopathy according to the present invention, wherein the extract of the sassafras wine is extracted from a root sample of scutellaria, and is obtained by extracting an aqueous solution of ethanol having a volume percentage of 95%.

本發明之用以改善糖尿病視網膜病變之中草藥組合物,其、中,該當歸酒萃物係萃取自一當歸根部樣品,且係為由體積百分濃度為95%之一乙醇水溶液所萃取獲得。 The herbal composition for improving diabetic retinopathy of the present invention, wherein the Angelica sinensis extract is extracted from a root sample of Angelica sinensis, and is obtained by extracting an aqueous solution of ethanol having a volume percentage of 95%.

本發明之用以改善糖尿病視網膜病變之中草藥組合物,其中,該石斛水萃物係萃取自一石斛莖部樣品,且該石斛水萃物為由純水萃取一石斛莖部樣品所獲得。 The herbal composition for improving diabetic retinopathy according to the present invention, wherein the aqueous extract of Dendrobium is extracted from a stem sample of Dendrobium, and the Dendrobium aqueous extract is obtained by extracting a sample of Dendrobium stem from pure water.

本發明之用以改善糖尿病視網膜病變之中草藥組合物,其中,該石斛水萃物係由包含以下步驟之方法所製得:於50~80℃下,以純水萃取該石斛莖部樣品,以獲得一石斛萃取液;及於50~80℃下,將該石斛水萃液與體積百分濃度為95%之一乙醇水溶液進行分配萃取,以獲得一沉澱物,該沉澱物即為該石斛水萃物。 The herbal composition for improving diabetic retinopathy according to the present invention, wherein the aqueous extract of Dendrobium is obtained by a method comprising the steps of: extracting the sample of the sarcophagus stem with pure water at 50 to 80 ° C, Obtaining a Dendrobium extract; and extracting and extracting the Dendrobium aqueous extract with an aqueous solution of 95% by volume of ethanol at 50-80 ° C to obtain a precipitate, the precipitate being the Dendrobium water Extract.

一種中草藥組合物之用途,係應用於製備改善糖尿病視網膜病變的藥物,該中草藥組合物係投予一所需生物體,以改善該所需升物體 之糖尿病視網膜病變現象,其中,該中草藥組合物係為如上述之中草藥組合物。 A use of a Chinese herbal medicine composition for preparing a medicament for improving diabetic retinopathy, the Chinese herbal medicine composition being administered to a desired organism to improve the desired lifting object The phenomenon of diabetic retinopathy, wherein the Chinese herbal medicine composition is a herbal composition as described above.

本發明之中草藥組合物之用途,其中,該中草藥組合物係以每天每公斤所需個體體重100毫克之劑量投予該所需個體,且連續投予15~60天。 The use of the herbal composition of the present invention, wherein the Chinese herbal medicine composition is administered to the individual in need at a dose of 100 mg per kg of the desired individual per day, and is administered continuously for 15 to 60 days.

本發明之用以改善糖尿病視網膜病變之中草藥組合物,係富含有阿魏酸及多醣,可以改善糖尿病視網膜病變現象,達到防止患者之視力持續惡化的功效。 The herbal composition for improving diabetic retinopathy of the present invention is rich in ferulic acid and polysaccharide, can improve the phenomenon of diabetic retinopathy, and achieve the effect of preventing the patient's vision from continuously deteriorating.

本發明之中草藥組合物之用途,係以富含有阿魏酸及多醣之中草藥組合物作為改善糖尿病視網膜病變之活性成份,防止習用藥物所導致之副作用的衍生,為本發明之功效。 The use of the herbal composition of the present invention is a derivative of a herbal composition rich in ferulic acid and a polysaccharide as an active ingredient for improving diabetic retinopathy and preventing side effects caused by conventional drugs, and is an effect of the present invention.

第1圖:係第C0~C4組大鼠於第1、15、30、45、60天之眼壓變化。 Fig. 1 shows changes in intraocular pressure on the 1st, 15th, 30th, 45th and 60th day of the rats in the C0~C4 group.

第2a圖:係第C0組大鼠於第1天之眼底攝影結果。 Fig. 2a: Photograph of the fundus of the group C0 rats on the first day.

第2b圖:係第C0組大鼠於第15天之眼底攝影結果。 Figure 2b: Results of fundus photography on day 15 of group C0 rats.

第2c圖:係第C0組大鼠於第30天之眼底攝影結果。 Figure 2c: Photograph of the fundus of the group C0 rats on the 30th day.

第2d圖:係第C0組大鼠於第45天之眼底攝影結果。 Figure 2d: Results of fundus photography on day 45 of group C0 rats.

第2e圖:係第C0組大鼠於第60天之眼底攝影結果。 Figure 2e: Results of fundus photography on day 60 of group C0 rats.

第3a圖:係第C1組大鼠於第1天之眼底攝影結果。 Fig. 3a: Results of fundus photography on day 1 of group C1 rats.

第3b圖:係第C1組大鼠於第15天之眼底攝影結果。 Fig. 3b: Results of fundus photography on day 15 of group C1 rats.

第3c圖:係第C1組大鼠於第30天之眼底攝影結果。 Figure 3c: Results of fundus photography on day 30 of group C1 rats.

第3d圖:係第C1組大鼠於第45天之眼底攝影結果。 Fig. 3d: Results of fundus photography on day 45 of group C1 rats.

第3e圖:係第C1組大鼠於第60天之眼底攝影結果。 Fig. 3e: Results of fundus photography on day 60 of group C1 rats.

第4a圖:係第C2組大鼠於第1天之眼底攝影結果。 Figure 4a: Results of fundus photography on day 1 of group C2 rats.

第4b圖:係第C2組大鼠於第15天之眼底攝影結果。 Figure 4b: Results of fundus photography on day 15 of group C2 rats.

第4c圖:係第C2組大鼠於第30天之眼底攝影結果。 Figure 4c: Results of fundus photography on day 30 of group C2 rats.

第4d圖:係第C2組大鼠於第45天之眼底攝影結果。 Fig. 4d: Photograph of the fundus of the group C2 rats on the 45th day.

第4e圖:係第C2組大鼠於第60天之眼底攝影結果。 Figure 4e: Results of fundus photography on day 60 of group C2 rats.

第5a圖:係第C3組大鼠於第1天之眼底攝影結果。 Fig. 5a: Results of fundus photography on day 1 of group C3 rats.

第5b圖:係第C3組大鼠於第15天之眼底攝影結果。 Figure 5b: Results of fundus photography on day 15 of group C3 rats.

第5c圖:係第C3組大鼠於第30天之眼底攝影結果。 Figure 5c: Results of fundus photography on day 30 of group C3 rats.

第5d圖:係第C3組大鼠於第45天之眼底攝影結果。 Fig. 5d: Results of fundus photography on day 45 of group C3 rats.

第5e圖:係第C3組大鼠於第60天之眼底攝影結果。 Figure 5e: Results of fundus photography on day 60 of group C3 rats.

第6a圖:係第C4組大鼠於第1天之眼底攝影結果。 Fig. 6a: Results of fundus photography on day 1 of group C4 rats.

第6b圖:係第C4組大鼠於第15天之眼底攝影結果。 Figure 6b: Results of fundus photography on day 15 of group C4 rats.

第6c圖:係第C4組大鼠於第30天之眼底攝影結果。 Figure 6c: Results of fundus photography on day 30 of group C4 rats.

第6d圖:係第C4組大鼠於第45天之眼底攝影結果。 Fig. 6d: Results of fundus photography on day 45 of group C4 rats.

第6e圖:係第C4組大鼠於第60天之眼底攝影結果。 Figure 6e: Results of fundus photography on day 60 of group C4 rats.

為讓本發明之上述及其他目的、特徵及優點能更明顯易懂,下文特舉本發明之較佳實施例,並配合所附圖式,作詳細說明如下:本發明之一實施例的中草藥組合物係包含:以重量百分比計為40%之一黃耆酒萃物、8%之一當歸酒萃物及52%之一石斛水萃物,藉由該中草藥組合物所富含之阿魏酸及多醣等活性成分,可以改善患者之糖尿病視網膜病變現象。 The above and other objects, features and advantages of the present invention will become more <RTIgt; The composition comprises: 40% by weight of a sassafras extract, 8% of an angelica extract and 52% of an aqueous extract of Dendrobium, and the fermented by the Chinese herbal composition Active ingredients such as acid and polysaccharide can improve diabetic retinopathy in patients.

該黃耆酒萃物、該當歸酒萃物及該石斛水萃物之萃取方法係為本發明所屬技術領域中具有通常知識者依需求所能夠調整,於此不加以設限。詳而言之,該黃耆酒萃物係萃取自一黃耆根部樣品,例如由體積百分濃度為95%之一乙醇水溶液所萃取獲得;該當歸酒萃物則萃取自一當歸 根部樣品,亦可以由體積百分濃度為95%之一乙醇水溶液所萃取獲得。於本實施例中,係混合1kg之黃耆根部樣品及200g之當歸根部樣品後,以4L之乙醇水溶液(體積百分濃度為95%)進行萃取。 The extract of the sassafras wine, the extract of the angelica wine and the extraction method of the aqueous extract of the sarcophagus are adjusted according to the needs of those having ordinary knowledge in the technical field of the invention, and are not limited thereto. In detail, the extract of the sassafras wine is extracted from a root sample of a scutellaria, for example, extracted by an aqueous solution of 95% by volume of an aqueous solution of ethanol; The root sample can also be obtained by extracting from a 95% by volume aqueous solution of ethanol. In the present example, 1 kg of the xanthium root sample and 200 g of the angelica root sample were mixed, and then extracted with 4 L of an aqueous ethanol solution (95% by volume).

又,該石斛水萃物係萃取自一石斛莖部樣品,如由純水所萃取獲得,例如能夠於50~80℃下,以純水萃取該石斛莖部樣品,以獲得一石斛萃取液,續於50~80℃下,將該石斛水萃液與該乙醇水溶液(體積百分濃度為95%)進行分配萃取,取得其沉澱物,即為該石斛水萃物。於本實施例中,係以4L之純水混合1kg之石斛莖部樣品,加熱萃取2小時,將獲得之石斛萃取液減壓濃縮至體積為1L,續加入3L之乙醇水溶液(體積百分濃度為95%,優先置於4℃降溫),沉澱一晚後,以12,000rpm之轉速離心20分鐘,去除上清液後,即可以取得該石斛水萃物。 Further, the Dendrobium water extract is extracted from a stem sample of a Dendrobium, and is obtained by extracting pure water, for example, the stem sample of the Dendrobium can be extracted with pure water at 50-80 ° C to obtain a Dendrobium extract. The aqueous extract of Dendrobium candidum and the aqueous solution of ethanol (95% by volume) were subjected to partition extraction at 50-80 ° C to obtain a precipitate, which is the aqueous extract of Dendrobium. In the present embodiment, a 1 kg sample of Dendrobium candidum was mixed with 4 L of pure water, and the extract was heated for 2 hours, and the obtained Dendrobium extract was concentrated under reduced pressure to a volume of 1 L, and 3 L of an aqueous ethanol solution (volume percent concentration) was continuously added. It is 95%, preferably placed at 4 ° C to cool down. After one night of precipitation, it is centrifuged at 12,000 rpm for 20 minutes. After removing the supernatant, the aqueous extract of Dendrobium can be obtained.

本發明之中草藥組合物係可以有效修復高血糖所導致之視網膜細胞的損傷現象,因而係能夠作為一種改善糖尿病視網膜病變之活性成分,例如可以將該中草藥組合物應用於製備改善糖尿病視網膜病變之藥物或保健食品,該中草藥組合物與醫藥學上可以接受之載劑或賦形劑組合形成一醫藥組合物,其中,該中草藥組合物係可以製備成任何方便食用之型式,如錠劑、膠囊、粉劑、粒劑或液劑等,或者將該中草藥組合物與其他食品或飲料組合,以一適於食用之樣態供生物體以口服方式服用。 The herbal composition of the present invention can effectively repair the damage of retinal cells caused by hyperglycemia, and thus can be used as an active ingredient for improving diabetic retinopathy, for example, the Chinese herbal medicine composition can be applied to prepare a drug for improving diabetic retinopathy. Or a health food product, the Chinese herbal medicine composition is combined with a pharmaceutically acceptable carrier or excipient to form a pharmaceutical composition, wherein the Chinese herbal medicine composition can be prepared into any convenient form such as a tablet, a capsule, or the like. A powder, a granule or a liquid, or the like, or a combination of the Chinese herbal composition with other foods or beverages, for oral administration to the organism in a form suitable for consumption.

又,該中草藥組合物係可以供投予一所需個體,例如以每天每公斤之所需個體體重投予100mg之中草藥組合物,且連續投予該所需個體15~60天,使阿魏酸及多醣等活性成分得以於該所需個體體內作用,而可以改善該所需個體之糖尿病視網膜病變現象。 Further, the Chinese herbal medicine composition can be administered to a desired individual, for example, by administering 100 mg of the Chinese herbal medicine composition per kg of the desired individual body weight per day, and continuously administering the desired individual for 15 to 60 days to make the Awei Active ingredients such as acids and polysaccharides can act in the desired individual, and can improve the diabetic retinopathy of the desired individual.

為證實本發明中草藥組合物確實具有改善糖尿病視網膜病變現象之活性,遂進行以下試驗: In order to confirm that the Chinese herbal medicine composition of the present invention does have an activity of improving the phenomenon of diabetic retinopathy, the following tests were carried out:

(A)中草藥組合物之製備(A) Preparation of Chinese herbal medicine composition

本試驗中,係混合1kg之黃耆根部樣品及200g之當歸根部樣品,以4L升之乙醇水溶液(體積百分濃度為95%)進行萃取800分鐘,重複三次後,經真空過濾、減壓濃縮及冷凍乾燥後,共獲得98.52g之混合酒萃物(即,該黃耆酒萃物及該當歸酒萃物之混合物)。 In this test, 1 kg of Scutellaria root samples and 200 g of Angelica root samples were mixed, and extracted with 4 L of ethanol solution (95% by volume) for 800 minutes, repeated three times, vacuum filtered, concentrated under reduced pressure. After lyophilization, a total of 98.52 g of the mixed wine extract (i.e., the mixture of the sassafras extract and the extract of the angelica extract) was obtained.

另將4L升之純水混合1kg之石斛莖部樣品,加熱萃取2小時,將獲得之石斛萃取液減壓濃縮至體積為1kg,續加入3L之乙醇水溶液(體積百分濃度為95%,優先置於4℃降溫),沉澱一晚後,以12,000rpm之轉速離心20分鐘,去除上清液並烘乾後,即取得74.58g之石斛水萃物。 In addition, 4 L of pure water was mixed with 1 kg of the stem sample of Dendrobium, heated and extracted for 2 hours, and the obtained Dendrobium extract was concentrated under reduced pressure to a volume of 1 kg, and a 3 L aqueous solution of ethanol was added (95% by volume, priority After cooling at 4 ° C, the precipitate was centrifuged at 12,000 rpm for 20 minutes, and after removing the supernatant and drying, 74.58 g of the aqueous extract of Dendrobium was obtained.

續混合該混合萃取物及該石斛水萃物,以獲得本試驗之中草藥組合物,其中該中草藥組合物係包含以重量百分比計為40%之黃耆酒萃物、8%之當歸酒萃物及52%之石斛水萃物。 The mixed extract and the aqueous extract of Dendrobium sinensis are continuously mixed to obtain the herbal composition of the test, wherein the Chinese herbal medicine composition comprises 40% by weight of the extract of sassafras, 8% of the extract of Angelica sinensis And 52% of the water extract of Dendrobium.

(B)中草藥組合物之活性成分含量檢測(B) Detection of active ingredient content of Chinese herbal medicine composition

該中草藥組合物之阿魏酸含量之測定,係將1.608g之中草藥組合物溶於甲醇後,以0.45μm濾膜過濾濃縮,續以甲醇將總體積調整為10mL,以作為代測樣品。續選用Thermo ODS Hypersil(5μm)250mm*4.6mm管柱進行分析,以18:82之體積比混合乙腈(Acetonitrile,簡稱ACN)及0.05%之磷酸溶液作為流動相,流速為1mL/min,偵測波長為320nm之吸光值,並分析阿魏酸占總面積之百分比,並比照已知濃度之阿魏酸溶液所繪製之檢量線,其結果顯示,該中草藥組合物之阿魏酸含量為42.255±5.655μg/g。 The ferulic acid content of the Chinese herbal medicine composition was determined by dissolving 1.608 g of the Chinese herbal medicine composition in methanol, and then filtering and concentrating with a 0.45 μm filter, and then adjusting the total volume to 10 mL with methanol as a substitute sample. Continued selection of Thermo ODS Hypersil (5μm) 250mm*4.6mm column, mixing acetonitrile (Acetonitrile, ACN for short) and 0.05% phosphoric acid solution as mobile phase at a flow rate of 1mL/min. The absorbance at a wavelength of 320 nm, and the percentage of ferulic acid in the total area, and the calibration curve drawn from the known concentration of ferulic acid solution, the result shows that the ferulic acid content of the Chinese herbal composition is 42.255. ±5.655 μg/g.

另以酚-硫酸法(phenol-sulfuric acid method)進行該中草藥組合物之多醣含量測定,係以100mL之熱水稀釋200mg之中草藥組合物後,分別取體積為0.3mL、0.4mL、0.5mL、0.6mL、0.7mL、0.8mL之稀釋液,加入等體積之5%酚溶液及5倍體積之濃硫酸溶液,混合震盪並 靜置30分鐘後,偵測波長為490nm之吸光值,並比照已知濃度之葡萄糖溶液所繪製之檢量線,得知該中草藥組合物之多醣含量為14.667μg/g(以〝每克中草藥組合物所含有之葡萄糖含量〞作為比較基準)。 Further, the polysaccharide content of the Chinese herbal medicine composition is determined by a phenol-sulfuric acid method, and after diluting 200 mg of the Chinese herbal medicine composition in 100 mL of hot water, the volume is 0.3 mL, 0.4 mL, and 0.5 mL, respectively. 0.6mL, 0.7mL, 0.8mL of the dilution, add an equal volume of 5% phenol solution and 5 times the volume of concentrated sulfuric acid solution, mix and oscillate After standing for 30 minutes, the absorbance at a wavelength of 490 nm was detected, and the polysaccharide content of the Chinese herbal medicine composition was found to be 14.667 μg/g (see 〝 per gram of Chinese herbal medicine). The glucose content of the composition is used as a basis for comparison).

(C)對糖尿病大鼠之糖尿病視網膜病變的影響(C) Effects on diabetic retinopathy in diabetic rats

本試驗係選用購自財團法人國家實驗研究院國家實驗動物中心之Wistar雄性大鼠,該些大鼠皆在6~8週週齡,體重介於150~200克之間。該些大鼠係飼養於大仁科技大學動物中心,維持室溫為24±2℃、相對溼度為65±5%之動物室,光照時間與黑暗時間各為12小時,該些大鼠可以自由進食及飲水。 In this experiment, Wistar male rats purchased from the National Experimental Animal Center of the National Experimental Research Institute of the National Research Institute were selected. These rats were all 6 to 8 weeks old and weighed between 150 and 200 grams. The rats were housed in the animal center of Daren University of Science and Technology, and maintained an animal room with a room temperature of 24 ± 2 ° C and a relative humidity of 65 ± 5%. The light time and dark time were each 12 hours. The rats were free to eat. And drinking water.

請參照第1表所示,係將該些大鼠區分為第C0~C4組,另將第C1~C4組之大鼠於空腹72小時後,以腹腔注射(intraperitioneal injection)方式將鏈脲佐菌素(streptozotocin,簡稱STZ)投予該些大鼠(投予劑量為60mg/kg),以誘導形成糖尿病大鼠,續於72小時後,量測該些大鼠之血糖值,血糖值高於300mg/L,且出現三多症狀(多吃、多喝、多尿)之大鼠即可以視為成功誘導為第一型糖尿病大鼠。 Please refer to the first table, the rats are divided into the C0~C4 group, and the rats in the C1~C4 group are subjected to intraperitoneal injection (intraperitioneal injection) for 72 hours. Streptozotocin (STZ for short) was administered to the rats (administered at a dose of 60 mg/kg) to induce the formation of diabetic rats. After 72 hours, the blood glucose levels of the rats were measured and the blood glucose level was high. Rats at 300 mg/L and with more than three symptoms (eat more, drink more, more urine) can be considered to be successfully induced into type 1 diabetic rats.

分別將如第1表所示之中草藥組合物經口餵食各組大鼠,每天餵食1次,連續餵食60天,並分別評估糖尿病視網膜病變情形。 The Chinese herbal medicine composition as shown in Table 1 was orally administered to each group of rats, fed once a day for 60 days, and the diabetic retinopathy was evaluated separately.

於第1、15、30、45及60天時,分別以乙醚麻醉各組大鼠, 量測其眼壓,結果如第1圖所示,第15天起,第C1組大鼠之眼壓約維持於20mmHg,而連續餵食該中草藥組合物(即,第C4組)則可以顯著降低大鼠之眼壓數值。 On days 1, 15, 30, 45 and 60, rats in each group were anesthetized with ether, respectively. The intraocular pressure was measured, and as shown in Fig. 1, the eye pressure of the C1 group rats was maintained at about 20 mmHg from the 15th day, and the continuous feeding of the Chinese herbal medicine composition (i.e., the C4 group) was significantly reduced. The intraocular pressure value of the rat.

另第1、15、30、45及60天時,於點入硫酸阿托平(atropine,0.25%)點眼液後,以乙醚麻醉各組糖尿病大鼠,並於5分鐘後以眼底鏡(MiiS Horus Scope DOC100)進行各組糖尿病大鼠之眼底攝影,結果分別如第2a~2e圖(第C0組大鼠)、第3a~3e圖(第C1組大鼠)、第4a~4e圖(第C2組大鼠)、第5a~5e圖(第C3組大鼠)、第6a~6e圖(第C4組大鼠)、所示。 On the 1st, 15th, 30th, 45th and 60th day, after atropine (0.25%) eye drops were added, each group of diabetic rats was anesthetized with ether, and after 5 minutes, the ophthalmoscope was used ( MiiS Horus Scope DOC100) The fundus photography of each group of diabetic rats was performed as shown in Fig. 2a~2e (C0 group rats), 3a~3e pictures (C1 group rats), and 4a~4e pictures ( Group C2 rats), pictures 5a-5e (group C3 rats), and pictures 6a-6e (group C4 rats), shown.

請參照第2a~2e圖所示,第C0組大鼠之視網膜並未出現糖尿病視網膜病變之病徵,續參照第3a~3e圖所示,第C1組大鼠於第30天後開始出現糖尿病視網膜病變之徵兆,如視網膜內微血管異常(intraretinal microvascular abnormalities,簡稱IRMA)及視網膜出血(retinal hemorrhage)等現象,另請參照第4a~4e及5a~5e圖所示,第C2、C3組大鼠於30天後雖亦有出現糖尿病視網膜病變之徵兆,惟其狀態已較第C1組大鼠略為緩和,而第6a~6e圖所示之第C4組大鼠,其視網膜狀態與第C0組大鼠無異,顯示本發明中草藥組合物確實可以改善糖尿病視網膜病變之狀態。 Please refer to the figures 2a~2e. The retina of the group C0 does not show signs of diabetic retinopathy. Continue to refer to the 3a~3e chart. The rats in the C1 group start to develop the diabetic retina after the 30th day. Symptoms of lesions, such as intraretinal microvascular abnormalities (IRMA) and retinal hemorrhage, please refer to Figures 4a~4e and 5a~5e, in groups C2 and C3. Although there were signs of diabetic retinopathy after 30 days, the state was slightly more moderate than that of the C1 group, and the retinal state of the C4 group shown in Fig. 6a~6e was not the same as that of the group C0. The difference is that the Chinese herbal medicine composition of the present invention can indeed improve the state of diabetic retinopathy.

綜合上述,本發明之用以改善糖尿病視網膜病變之中草藥組合物,係富含有阿魏酸及多醣,可以改善糖尿病視網膜病變現象,達到防止患者之視力持續惡化的功效。 In summary, the herbal composition for improving diabetic retinopathy of the present invention is rich in ferulic acid and polysaccharide, which can improve the phenomenon of diabetic retinopathy and prevent the patient from continuously improving the vision.

再者,本發明之中草藥組合物之用途,係以富含有阿魏酸及多醣之中草藥組合物作為改善糖尿病視網膜病變之活性成份,防止習用藥物所導致之副作用的衍生,為本發明之功效。 Furthermore, the use of the herbal composition of the present invention is a derivative of a herbal composition rich in ferulic acid and a polysaccharide as an active ingredient for improving diabetic retinopathy and preventing side effects caused by conventional drugs, and is an effect of the present invention. .

雖然本發明已利用上述較佳實施例揭示,然其並非用以限定 本發明,任何熟習此技藝者在不脫離本發明之精神和範圍之內,相對上述實施例進行各種更動與修改仍屬本發明所保護之技術範疇,因此本發明之保護範圍當視後附之申請專利範圍所界定者為準。 Although the present invention has been disclosed using the above preferred embodiments, it is not intended to be limiting The present invention is not limited to the spirit and scope of the present invention, and various modifications and changes to the above embodiments are still within the technical scope of the present invention. Therefore, the scope of protection of the present invention is attached. The scope defined in the scope of application for patent application shall prevail.

Claims (7)

一種用以改善糖尿病視網膜病變之中草藥組合物,係包含:以重量百分比計為40%之一黃耆酒萃物、8%之一當歸酒萃物及52%之一石斛水萃物。 A herbal composition for improving diabetic retinopathy comprises: 40% by weight of a sassafras extract, 8% of an angelica extract and 52% of an aqueous extract of Dendrobium. 如申請專利範圍第1項所述之用以改善糖尿病視網膜病變之中草藥組合物,其中,該黃耆酒萃物係萃取自一黃耆根部樣品,且係為由體積百分濃度為95%之一乙醇水溶液所萃取獲得。 The herbal composition for improving diabetic retinopathy according to claim 1, wherein the extract of the sassafras is extracted from a root sample of scutellaria and is 95% by volume. It is obtained by extraction with an aqueous solution of ethanol. 如申請專利範圍第1項所述之用以改善糖尿病視網膜病變之中草藥組合物,其中,該當歸酒萃物係萃取自一當歸根部樣品,且係為由體積百分濃度為95%之一乙醇水溶液所萃取獲得。 The herbal composition for improving diabetic retinopathy according to claim 1, wherein the angelica extract is extracted from a root sample of Angelica sinensis and is one of 95% by volume ethanol. Extracted from an aqueous solution. 如申請專利範圍第1項所述之用以改善糖尿病視網膜病變之中草藥組合物,其中,該石斛水萃物係萃取自一石斛莖部樣品,且該石斛水萃物為由純水萃取一石斛莖部樣品所獲得。 The herbal composition for improving diabetic retinopathy according to claim 1, wherein the aqueous extract of Dendrobium is extracted from a stem sample of Dendrobium, and the aqueous extract of Dendrobium is extracted from pure water. Stem samples were obtained. 如申請專利範圍第4項所述之用以改善糖尿病視網膜病變之中草藥組合物,其中,該石斛水萃物係由包含以下步驟之方法所製得:於50~80℃下,以純水萃取該石斛莖部樣品,以獲得一石斛萃取液;及於50~80℃下,將該石斛水萃液與體積百分濃度為95%之一乙醇水溶液進行分配萃取,以獲得一沉澱物,該沉澱物即為該石斛水萃物。 The herbal composition for improving diabetic retinopathy as described in claim 4, wherein the aqueous extract of Dendrobium is obtained by a method comprising the steps of: extracting at 50-80 ° C with pure water The sarcophagus stem sample is obtained to obtain a sarcophagus extract; and the aqueous extract of the sarcophagus is distributed and extracted with an aqueous solution of 95% by volume of ethanol at 50-80 ° C to obtain a precipitate. The precipitate is the aqueous extract of Dendrobium. 一種中草藥組合物之用途,係應用於製備改善糖尿病視網膜病變的藥物,該中草藥組合物係投予一所需生物體,以改善該所需升物體之糖尿病視網膜病變現象,其中,該中草藥組合物係為如申請專利範圍第1~5項之任一項所述之中草藥組合物。 A use of a Chinese herbal medicine composition for preparing a medicament for improving diabetic retinopathy, wherein the Chinese herbal medicine composition is administered to a desired organism to improve the diabetic retinopathy of the desired ascending object, wherein the Chinese herbal medicine composition The herbal composition according to any one of the items 1 to 5 of the patent application. 如申請專利範圍第6項所述之中草藥組合物之用途,其中,該中草藥組合物係以每天每公斤所需個體體重100毫克之劑量投予該所需個 體,且連續投予15~60天。 The use of the herbal composition according to claim 6, wherein the Chinese herbal composition is administered at a dose of 100 mg per kg of the desired individual per day. Body, and continuous administration for 15 to 60 days.
TW104104573A 2015-02-11 2015-02-11 An herbal composition for improving diabetic retinopathy and a use of the herbal composition thereof TW201628635A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW104104573A TW201628635A (en) 2015-02-11 2015-02-11 An herbal composition for improving diabetic retinopathy and a use of the herbal composition thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW104104573A TW201628635A (en) 2015-02-11 2015-02-11 An herbal composition for improving diabetic retinopathy and a use of the herbal composition thereof

Publications (1)

Publication Number Publication Date
TW201628635A true TW201628635A (en) 2016-08-16

Family

ID=57181989

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104104573A TW201628635A (en) 2015-02-11 2015-02-11 An herbal composition for improving diabetic retinopathy and a use of the herbal composition thereof

Country Status (1)

Country Link
TW (1) TW201628635A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111588728A (en) * 2019-02-20 2020-08-28 安益药业股份有限公司 Medicinal composition, dendrobe extract and application of medicinal composition

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111588728A (en) * 2019-02-20 2020-08-28 安益药业股份有限公司 Medicinal composition, dendrobe extract and application of medicinal composition
US11576918B2 (en) 2019-02-20 2023-02-14 AMX Pharma Inc. Pharmaceutical composition and extract of Dendrobii Caulis with eye care effect and uses of preparing the same thereof

Similar Documents

Publication Publication Date Title
US10111451B2 (en) Food, beverage or pharmaceutical composition containing fermented eastern prickly pear and a preparation method therefor
CN102764408B (en) Dealcoholic preparation
US11351184B2 (en) Preparation of Pulsatilla saponin B4 for injection
CN104041615A (en) Blood-pressure-lowering health tea
CN103893571B (en) A kind of pharmaceutical composition for treating hypertension and its application
JP2011522844A (en) Composition for reducing blood glucose level and use thereof
CN103301146B (en) Traditional Chinese medicine monomer combination capable of resisting oxidation and improving eyeground blood circulation
US10561699B2 (en) Method for treating diabetic retinopathy
CN112089784A (en) Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis
TW201628635A (en) An herbal composition for improving diabetic retinopathy and a use of the herbal composition thereof
CN101152223B (en) Use of poplar leaf phenols extract in preparation of medicine for treating cardiovascular disease
CN105168739B (en) A kind of treat hypertension, hyperlipidemia, hyperglycemia and the compositions of resisting fatigue improving eyesight
JP6444688B2 (en) Swelling suppression or improvement agent
CN107854609A (en) Red ginseng, the tuber of dwarf lilyturf, fruit of Chinese magnoliavine composition are used for the purposes for preparing the medicine for the treatment of depression
CN101278940A (en) Medicament composition for curing diabetic cardiovascular pathological changes and method of preparing the same
TW200938216A (en) Use of black soybean for treating ophthalmic diseases
CN104258034A (en) Traditional Chinese medicine composition for boosting immunity
EP1581195A1 (en) Film coated tablet comprising an extract of red vine leaves
CN106692289B (en) Medical application of barbat skullcap alcohol extract
CN105380985B (en) Pharmaceutical composition for treating cerebral arterial thrombosis
KR20150018167A (en) A pharmaceutical composition comprising fermented Eastern prickly pear
CN111096985A (en) Blood pressure and blood sugar regulating and reducing composition and application of herba lysimachiae extract
CN109771631A (en) A kind of wrinkled giant hyssop ginger jujube composition and preparation method thereof
KR102265793B1 (en) Health functional food composition containing extract of Antirrhinum majus L. as an active ingredient for lowering blood glucose
JP6511604B2 (en) Method for producing metabolic syndrome therapeutic agent